AMRN on pace to crush estimates on MARINE sales alone. Vascepa treats people in a four million person population many of whom cannot take Lovaza due to high LDL-C. That's a gargantuan market. ANCHOR isn't in any numbers yet.
frenzy I just wanted to take a minute to thank you for all your well thought out and fact filled posts over the last few months during an extremely rough stretch here I for one always enjoy reading your posts. I have seen NOTHING so far tracking script growth that has led me to believe we don't have a winner here heck we are 4 months in and almost at a 5k run rate with only 250 reps and no BP backing us for crying out loud!!! Oh and just for the record I have seen what a HORRIBLE launch looks like I was in AVNR from day one of the launch it has taken them 3 years to get the same run rate AMRN has now and here's the kicker is they are almost have a $5 PPS now.
Not for nothing but it is a stretch to compare avnr to armn. You are talking about a cholesterol drug versus a drug for a little known condition called PBA. The comparison ends at 2 smalltime biotech companies.